Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma, T-Cell 4Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Small Cell Lung Carcinoma 2Sezary Syndrome 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Congenital Abnormalities 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

Tretinoin 10Arsenic Trioxide 10Methotrexate 7Busulfan 7Gemtuzumab 6Cytarabine 6Cyclophosphamide 6Peripheral Blood Stem Cell Transplantation 5Filgrastim 5fludarabine phosphate 4Idarubicin 4Tacrolimus 3Etoposide 3Daunorubicin 3Antilymphocyte Serum 3lintuzumab 2Topotecan 2Radiotherapy 2Mycophenolic Acid 2Mercaptopurine 2Cyclosporins 2Cyclosporine 2Bortezomib 2Azacitidine 2thymoglobulin 1tamibarotene 1sargramostim 1romidepsin 1merphos 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Promyelocytic, Acute × romidepsin × Clear all
NCT00062075 2015-12-04

Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡